lcz696 + sildenafil

LCZ696 + sildenafil refers to the combined use of **sacubitril/valsartan (brand name: Entresto, code name: LCZ696), an angiotensin receptor neprilysin inhibitor (ARNI), and sildenafil, a phosphodiesterase-5 (PDE5) inhibitor**. This combination is not an approved fixed-dose combination product but has been investigated in clinical pharmacology studies for potential drug-drug interactions, particularly in patients with heart failure and reduced ejection fraction (HFrEF) who may receive both agents. Sacubitril/valsartan acts by simultaneously inhibiting neprilysin (via sacubitril’s active metabolite LBQ657) and blocking angiotensin II type-1 (AT-1) receptors (via valsartan), leading to increased levels of natriuretic peptides and vasodilation, with enhanced activation of the guanylyl cyclase-coupled natriuretic peptide receptor and increased cyclic guanosine monophosphate (cGMP)[1][2][3]. Sildenafil inhibits PDE5, preventing degradation of cGMP, thereby promoting vasodilation and improved erectile function[2][3]. The combination can result in additive reduction in blood pressure and should be used cautiously due to the risk of hypotension[2][3][1].

Other names

sacubitril/valsartan + sildenafilentresto + sildenafil